68Ga-NYM032

N/A

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug Name68Ga-NYM032
Drug Alias Name68Ga-NYM03268GaNYM03268Ga-NY108
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Gallium > 68Ga +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsPositron-emission tomography enhancers
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsContrast agentsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWuxi Nuoyu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNorroy Bioscience Co LtdWuxi Nuoyu Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsContrast agentsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A